Asia-Pacific Sarcopenia Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Asia-Pacific sarcopenia treatment market is expected to reach USD 861,882.42 thousand by 2030 from USD 547,450.80 thousand in 2022, growing at a CAGR of 5.9% in the forecast period of 2023 to 2030.

Market Segmentation:

Asia-Pacific Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030.

Overview of Asia-Pacific Sarcopenia Treatment Market Dynamics

Driver
Rising prevalence of sarcopenia
Restrain
Lack of standardized diagnosis
Opportunity
Strategic initiatives by key market players

Market Players:

Some of the key market players operating in the Asia-Pacific sarcopenia treatment market are:

Abbott
Nestle Health Science (A subsidiary of Nestle S.A.)
Novartis AG
Sanofi
AstaReal Co., Ltd.
Haleon Group of Companies
BASF SE
Fermenta Biotech Limited
Healing Pharma India Pvt.Ltd
Metagenics
The Vitamin Company India
Wellona Pharma
Biophytis
ImmunoForge Inc.
ONCOCROSS CO., LTD.
OPKO Health, Inc.
Regeneron Pharmaceuticals Inc.
DSM

1 INTRODUCTION 22

1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET 22
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 24

2 MARKET SEGMENTATION 26

2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 33
2.8 MARKET END USER COVERAGE GRID 34
2.9 DBMR MARKET POSITION GRID 35
2.10 VENDOR SHARE ANALYSIS 36
2.11 SECONDARY SOURCES 37
2.12 ASSUMPTIONS 37

3 EXECUTIVE SUMMARY 38

4 PREMIUM INSIGHTS 41

4.1 PESTEL- 42
4.2 PORTER 43

5 REGULATIONS IN AUSTRALIA 44

6 MARKET OVERVIEW 45

6.1 DRIVERS 47
- 6.1.1 RISING PREVALENCE OF SARCOPENIA 47
- 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 47
- 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 48
6.2 RESTRAINTS 49
- 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 49
- 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 50
6.3 OPPORTUNITIES 50
- 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 50
- 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 51
6.4 CHALLENGES 51
- 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 51
- 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 52

7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 53

7.1 OVERVIEW 54
7.2 VITAMIN/DIETARY SUPPLEMENTS 57
- 7.2.1 VITAMIN SUPPLEMENTS 58
- 7.2.2 PROTEIN SUPPLEMENTS 58
- 7.2.3 FATTY ACID SUPPLEMENTS 58
- 7.2.4 CREATINE 58
- 7.2.5 WHEY PROTEINS 58
- 7.2.6 L-CARNITINE 58
- 7.2.7 SOY 58
- 7.2.8 BETA-ALANINE 58
- 7.2.9 OSTARINE 58
- 7.2.10 COLLAGEN PEPTIDES 59
- 7.2.11 LIGANDROL 59
- 7.2.12 BRANCH-CHAIN AMINO ACIDS 59
- 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 59
- 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 59
- 7.2.15 OTHERS 59
7.3 MEDICATIONS 60
- 7.3.1 OFF LABEL DRUGS 60
- 7.3.2 EMERGING DRUGS 60
  - 7.3.2.1 ACE INHIBITORS 60
    - 7.3.2.1.1 APPETITE STIMULANTS 61
    - 7.3.2.1.2 ORAL ANTIDIABETIC DRUGS 61
    - 7.3.2.1.3 OTHERS 61
7.4 OTHERS 61

8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE 62

8.1 OVERVIEW 63
8.2 PRIMARY SARCOPENIA 65
- 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 66
- 8.2.2 MEDICATIONS 66
- 8.2.3 OTHERS 66
8.3 SECONDARY SARCOPENIA 66
- 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 66
- 8.3.2 MEDICATIONS 66
- 8.3.3 OTHERS 67

9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES 68

9.1 OVERVIEW 69
9.2 PRE-SARCOPENIA 71
9.3 SARCOPENIA 71
9.4 SEVERE SARCOPENIA 71

10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 72

10.1 OVERVIEW 73
10.2 ORAL 75
10.3 INJECTABLES 75
10.4 OTHERS 76

11 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER 77

11.1 OVERVIEW 78
11.2 MALE 80
11.3 FEMALES 80

12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER 81

12.1 OVERVIEW 82
12.2 HOSPITALS 84
- 12.2.1 PUBLIC 84
- 12.2.2 PRIVATE 84
12.3 SPECIALTY CLINICS 85
12.4 HOME HEALTHCARE 85
12.5 OTHERS 85

13 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 86

13.1 OVERVIEW 87
13.2 DIRECT TENDER 89
13.3 RETAIL SALES 90
- 13.3.1 HOSPITAL PHARMACIES 90
- 13.3.2 ONLINE PHARMACIES 90
- 13.3.3 OTHERS 90
13.4 OTHERS 90

14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRIES 91

14.1 ASIA-PACIFIC 91
- 14.1.1 JAPAN 94
- 14.1.2 CHINA 99
- 14.1.3 SOUTH KOREA 104
- 14.1.4 INDIA 109
- 14.1.5 AUSTRALIA 114
- 14.1.6 SINGAPORE 119
- 14.1.7 THAILAND 124
- 14.1.8 MALAYSIA 129
- 14.1.9 INDONESIA 134
- 14.1.10 PHILIPPINES 139
- 14.1.11 VIETNAM 144
- 14.1.12 NEW ZEALAND 149
- 14.1.13 TAIWAN 154
- 1.3.1. REST OF ASIA-PACIFIC 159

15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, COMPANY 160

15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 160

16 SWOT ANALYSIS 161

17 COMPANY PROFILES 162

17.1 ABBOTT 162
- 17.1.1 COMPANY SNAPSHOT 162
- 17.1.2 REVENUE ANALYSIS 162
- 17.1.3 PRODUCT PORTFOLIO 163
- 17.1.4 RECENT DEVELOPMENT 163
17.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE S.A.) 164
- 17.2.1 COMPANY SNAPSHOT 164
- 17.2.2 REVENUE ANALYSIS 164
- 17.2.3 PRODUCT PORTFOLIO 165
- 17.2.4 RECENT DEVELOPMENT 165
17.3 NOVARTIS AG 166
- 17.3.1 COMPANY SNAPSHOT 166
- 17.3.2 REVENUE ANALYSIS 166
- 17.3.3 PRODUCT PORTFOLIO 167
- 17.3.4 PIPELINE PORTFOLIO 167
- 17.3.5 RECENT DEVELOPMENT 167
17.4 SANOFI 168
- 17.4.1 COMPANY SNAPSHOT 168
- 17.4.2 REVENUE ANALYSIS 168
- 17.4.3 PRODUCT PORTFOLIO 169
- 17.4.4 RECENT DEVELOPMENT 169
17.5 HALEON GROUP OF COMPANIES. 170
- 17.5.1 COMPANY SNAPSHOT 170
- 17.5.2 REVENUE ANALYSIS 170
- 17.5.3 PRODUCT PORTFOLIO 171
- 17.5.4 RECENT DEVELOPMENT 171
17.6 ASTAREAL CO., LTD. 172
- 17.6.1 COMPANY SNAPSHOT 172
- 17.6.2 PRODUCT PORTFOLIO 172
- 17.6.3 RECENT DEVELOPMENT 172
17.7 BASF SE 173
- 17.7.1 COMPANY SNAPSHOT 173
- 17.7.2 REVENUE ANALYSIS 173
- 17.7.3 PRODUCT PORTFOLIO 174
- 17.7.4 RECENT DEVELOPMENT 174
17.8 DSM 175
- 17.8.1 COMPANY SNAPSHOT 175
- 17.8.2 REVENUE ANALYSIS 175
- 17.8.3 PRODUCT PORTFOLIO 176
- 17.8.4 RECENT DEVELOPMENT 176
17.9 FERMENTA BIOTECH LIMITED 177
- 17.9.1 COMPANY SNAPSHOT 177
- 17.9.2 REVENUE ANALYSIS 177
- 17.9.3 PRODUCT PORTFOLIO 178
- 17.9.4 RECENT DEVELOPMENT 178
17.10 HEALING PHARMA INDIA PVT.IND. 179
- 17.10.1 COMPANY SNAPSHOT 179
- 17.10.2 PRODUCT PORTFOLIO 179
- 17.10.3 RECENT DEVELOPMENT 179
17.11 METAGENICS 180
- 17.11.1 COMPANY SNAPSHOT 180
- 17.11.2 PRODUCT PORTFOLIO 180
- 17.11.3 RECENT DEVELOPMENT 180
17.12 THE VITAMIN COMPANY INDIA 181
- 17.12.1 COMPANY SNAPSHOT 181
- 17.12.2 PRODUCT PORTFOLIO 181
- 17.12.3 RECENT DEVELOPMENT 181
17.13 WELLONA PHARMA 182
- 17.13.1 COMPANY SNAPSHOT 182
- 17.13.2 PRODUCT PORTFOLIO 182
- 17.13.3 RECENT DEVELOPMENT 182
17.14 BIOPHYTIS 183
- 17.14.1 COMPANY SNAPSHOT 183
- 17.14.2 PIPELINE PORTFOLIO 183
- 17.14.3 RECENT DEVELOPMENT 183
17.15 IMMUNOFORGE INC. 184
- 17.15.1 COMPANY SNAPSHOT 184
- 17.15.2 PIPELINE PORTFOLIO 184
- 17.15.3 RECENT DEVELOPMENT 184
17.16 ONCOCROSS CO., LTD. 185
- 17.16.1 COMPANY SNAPSHOT 185
- 17.16.2 PIPELINE PORTFOLIO 185
- 17.16.3 RECENT DEVELOPMENT 185
17.17 OPKO HEALTH, INC. 186
- 17.17.1 COMPANY SNAPSHOT 186
- 17.17.2 REVENUE ANALYSIS 186
- 17.17.3 PIPELINE PORTFOLIO 187
- 17.17.4 RECENT DEVELOPMENT 187
17.18 REGENERON PHARMACEUTICALS INC. 188
- 17.18.1 COMPANY SNAPSHOT 188
- 17.18.2 REVENUE ANALYSIS 188
- 17.18.3 PIPELINE PORTFOLIO 189
- 17.18.4 RECENT DEVELOPMENT 189

18 QUESTIONNAIRE 190

19 RELATED REPORTS 193

LIST OF TABLES

TABLE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 57
TABLE 2 ASIA-PACIFIC VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 57
TABLE 3 ASIA-PACIFIC MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 60
TABLE 4 ASIA-PACIFIC OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 60
TABLE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 6 ASIA-PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 7 ASIA-PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES , 2021-2030 (USD THOUSAND) 71
TABLE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND) 75
TABLE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER , 2021-2030 (USD THOUSAND) 80
TABLE 11 ASIA-PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 84
TABLE 12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND) 89
TABLE 13 ASIA-PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND) 90
TABLE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 93
TABLE 15 JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 16 JAPAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 17 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 18 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 94
TABLE 19 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 95
TABLE 20 JAPAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 95
TABLE 21 JAPAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 95
TABLE 22 JAPAN PRIMARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 23 JAPAN SECONDARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 24 JAPAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 96
TABLE 25 JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 96
TABLE 26 JAPAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 97
TABLE 27 JAPAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 97
TABLE 28 JAPAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 97
TABLE 29 JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 97
TABLE 30 JAPAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 98
TABLE 31 CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 32 CHINA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 33 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 34 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 99
TABLE 35 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 100
TABLE 36 CHINA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 37 CHINA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 38 CHINA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 39 CHINA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 40 CHINA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 101
TABLE 41 CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 101
TABLE 42 CHINA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 102
TABLE 43 CHINA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 102
TABLE 44 CHINA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 45 CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 102
TABLE 46 CHINA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 103
TABLE 47 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 48 SOUTH KOREA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 49 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 50 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 104
TABLE 51 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 105
TABLE 52 SOUTH KOREA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 53 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 54 SOUTH KOREA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 55 SOUTH KOREA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 56 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 106
TABLE 57 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 106
TABLE 58 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 107
TABLE 59 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 107
TABLE 60 SOUTH KOREA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 61 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 107
TABLE 62 SOUTH KOREA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 108
TABLE 63 INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 64 INDIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 65 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 66 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 109
TABLE 67 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 110
TABLE 68 INDIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 69 INDIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 70 INDIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 71 INDIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 72 INDIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 111
TABLE 73 INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 111
TABLE 74 INDIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 112
TABLE 75 INDIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 112
TABLE 76 INDIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 77 INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
TABLE 78 INDIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 113
TABLE 79 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 80 AUSTRALIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 81 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 82 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 114
TABLE 83 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 115
TABLE 84 AUSTRALIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 85 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 86 AUSTRALIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 87 AUSTRALIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 88 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 116
TABLE 89 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 116
TABLE 90 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 117
TABLE 91 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 117
TABLE 92 AUSTRALIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 93 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
TABLE 94 AUSTRALIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 118
TABLE 95 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 96 SINGAPORE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 97 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 98 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 119
TABLE 99 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 120
TABLE 100 SINGAPORE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 101 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 102 SINGAPORE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 103 SINGAPORE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 104 SINGAPORE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 121
TABLE 105 SINGAPORE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
TABLE 106 SINGAPORE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 122
TABLE 107 SINGAPORE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 122
TABLE 108 SINGAPORE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 109 SINGAPORE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 122
TABLE 110 SINGAPORE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 123
TABLE 111 THAILAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 112 THAILAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 113 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 114 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 124
TABLE 115 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 125
TABLE 116 THAILAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 117 THAILAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 118 THAILAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 119 THAILAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 120 THAILAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 126
TABLE 121 THAILAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 126
TABLE 122 THAILAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 127
TABLE 123 THAILAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
TABLE 124 THAILAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 125 THAILAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
TABLE 126 THAILAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 128
TABLE 127 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 128 MALAYSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 129 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 130 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 129
TABLE 131 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 130
TABLE 132 MALAYSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 133 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 134 MALAYSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 135 MALAYSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 136 MALAYSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 131
TABLE 137 MALAYSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 131
TABLE 138 MALAYSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 132
TABLE 139 MALAYSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
TABLE 140 MALAYSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 141 MALAYSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 132
TABLE 142 MALAYSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 143 INDONESIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 144 INDONESIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 145 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 146 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 134
TABLE 147 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 135
TABLE 148 INDONESIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 149 INDONESIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 150 INDONESIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 151 INDONESIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 152 INDONESIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 136
TABLE 153 INDONESIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 136
TABLE 154 INDONESIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 137
TABLE 155 INDONESIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
TABLE 156 INDONESIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 157 INDONESIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 158 INDONESIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 138
TABLE 159 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 160 PHILIPPINES MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 161 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 162 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 139
TABLE 163 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 140
TABLE 164 PHILIPPINES VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 165 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 166 PHILIPPINES PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 167 PHILIPPINES SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 168 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 141
TABLE 169 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
TABLE 170 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 142
TABLE 171 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 142
TABLE 172 PHILIPPINES HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 173 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 142
TABLE 174 PHILIPPINES RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 143
TABLE 175 VIETNAM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 176 VIETNAM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 177 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 178 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 144
TABLE 179 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 145
TABLE 180 VIETNAM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 181 VIETNAM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 182 VIETNAM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 183 VIETNAM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 184 VIETNAM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 146
TABLE 185 VIETNAM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 146
TABLE 186 VIETNAM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 147
TABLE 187 VIETNAM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 147
TABLE 188 VIETNAM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 189 VIETNAM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 147
TABLE 190 VIETNAM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 148
TABLE 191 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 192 NEW ZEALAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 193 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 194 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 149
TABLE 195 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 150
TABLE 196 NEW ZEALAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 197 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 198 NEW ZEALAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 199 NEW ZEALAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 200 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 151
TABLE 201 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 151
TABLE 202 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 152
TABLE 203 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 152
TABLE 204 NEW ZEALAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 205 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 152
TABLE 206 NEW ZEALAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 153
TABLE 207 TAIWAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 208 TAIWAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 209 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 210 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS) 154
TABLE 211 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP) 155
TABLE 212 TAIWAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 213 TAIWAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 214 TAIWAN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 215 TAIWAN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 216 TAIWAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 156
TABLE 217 TAIWAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 156
TABLE 218 TAIWAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 157
TABLE 219 TAIWAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 157
TABLE 220 TAIWAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 157
TABLE 221 TAIWAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
TABLE 222 TAIWAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 158
TABLE 223 REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 159

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION 26
FIGURE 2 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION 28
FIGURE 3 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DROC ANALYSIS 29
FIGURE 4 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS 30
FIGURE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 30
FIGURE 6 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 31
FIGURE 7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID 34
FIGURE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID 35
FIGURE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION 40
FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030 41
FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SARCOPENIA MARKET IN 2023 AND 2030 41
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET 46
FIGURE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022 54
FIGURE 15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 55
FIGURE 16 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 55
FIGURE 17 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE 56
FIGURE 18 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2022 63
FIGURE 19 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 64
FIGURE 20 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 64
FIGURE 21 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE 65
FIGURE 22 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2022 69
FIGURE 23 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND) 70
FIGURE 24 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030) 70
FIGURE 25 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE 71
FIGURE 26 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 73
FIGURE 27 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 74
FIGURE 28 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 74
FIGURE 29 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 75
FIGURE 30 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2022 78
FIGURE 31 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 79
FIGURE 32 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030) 79
FIGURE 33 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE 80
FIGURE 34 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2022 82
FIGURE 35 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 83
FIGURE 36 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030) 83
FIGURE 37 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE 84
FIGURE 38 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 87
FIGURE 39 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 88
FIGURE 40 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 88
FIGURE 41 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 89
FIGURE 42 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022) 91
FIGURE 43 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%) 160